Sartar was selected to participate as one of the rising stars at Nordic Life Science Invest, 19 April 2021!
The Board of Directors of Sartar Therapeutics has appointed Katja Ivanitskiy as the new CEO of Sartar Therapeutics as of 9 November 2020.
Sartar warmly welcomes Katja to the company!
Sartar has been selected as one of only six finalists at the NOME Startup Competition 2020, November 18.
Sartar was selected among close to 100 other companies who also applied to the competition.
Successful investment round!
Sartar’s investment round closed ahead of time on Monday (19.10.2020). We achieved incredible outcome of 2 300 000 euros just in six days.
Sartar wishes to thank all investors for taking part in the round. We would also like to thank Springvest, for helping us to achieve this goal. Thank you!
Sartarin rahoituskierros on auki! / Sartar’s financing round is open!
Sartar was chosen among the top 30 innovative life science companies in RESI Europe 2020 innovation challenge
RESI Europe 2020 Innovation Challenge – Check Out the Finalists!
Sartar in Business Finland pitching competition in HealthBIO Partnering day, May 16
https://www.turunmessukeskus.fi/en/event/life-science-live/
Sartar was chosen to Kasvu Open – Future Health and Wellbeing program
Read more about the program (Finnish).
The Anglonordic Life Science Conference LONDON, May 9, 2019
Meet us at the Anglonordic Life Science Conference in London.
http://anglonordic.biopartnering.co.uk/
Sartar will pitch at Seed Forum Helsinki, April 9, 2019
https://www.seedforumhelsinki.com/seed-forum-helsinki
Sartar was awarded a Japan patent 25.1.2019
Sartar was awarded a Japan patent for use of anagrelide in cancer therapy.
Pekka Simula joins Sartar’s board of directors
Sartar strengthens the board of directors. CEO of Herantis Pharma, Pekka Simula, has been appointed as a new member to the Sartar Therapeutics board of directors.
BioInvestor Forum and Global SPARK Showcase, San Franscisco, California, October 16-18, 2018
Sartar will pitch at BioInvestor Forum and Global SPARK Showcase events. Meet us there!
https://www.bio.org/events/bio-investor-forum
https://www.bio.org/events/bio-investor-forum/spark-showcase
The Anglonordic Life Science Conference LONDON, May 24, 2018
Meet us at the Anglonordic Life Science Conference in London.
http://anglonordic.biopartnering.co.uk/
Charité BIH Entrepreneurship Summit Berlin, May 7 – 8, 2018
Sartar will pitch at the Life Sciences Venture Market 2018!
http://www.stiftung-charite.de/en/events/charite-entrepreneurship-summit.html
The 2nd KYOTO−SPARK Symposium February 14, 2018
Sartar will give a presentation at the 2nd KYOTO−SPARK Symposium.
http://www.kyoto-spark.med.kyoto-u.ac.jp/newsen/20171227161216/
Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation
The Vice-Chairman of the Board and a co-founder the Sartar Therapeutics Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation. Congratulations Heikki on your new appointment!
Sartar was awarded a U.S. patent 16.10.2017
Sartar was awarded a USA patent for use of anagrelide in cancer therapy.
Sartar won HealthBIO pitching competition 9.10.2017
Sartar Therapeutics participated to the HealthBIO pitching competition and won it.
http://turkusciencepark.com/spark-uutiset/1673/suomalaisen-life-science-alan-vienti-vahvassa-ka/
BIO-Europe Berlin November 6–8, 2017
Sartar will participate in the Next Generation tract company presentations in the BIO-Europe conference at Wednesday 8th of November.
https://ebdgroup.knect365.com/bioeurope/
HealthBIO Seminar and Partnering Event in Turku 5-6.9.2017
Sartar participates in HealthBIO partnering event.
Sartar was chosen to SPARK Finland program starting at 2.5.2017
SPARK Finland program is designed to increase the maturity of academic and clinical discoveries towards practical solutions in the life science and health tech space.
Sartar starts at Life Science Accelerator program in Turku 27.3.2017
Life Science Accelerator is a national initiative to access the untapped innovation potential within university research and young companies and to create new successful business. The initiative is partly funded by ERDF funding.
